Naftopidil vs tamsulosin
- Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes onlyno estimate extracted12 studies · 965 participantsModerate
Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).
It is very uncertain whether naftopidil changes treatment withdrawals for any reason compared with eviprostat (phytotherapy) (very low certainty).
It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).
Naftopidil showed no clear difference in treatment withdrawals for any reason compared with tamsulosin (alpha‐blocker) (low certainty).
Naftopidil showed no clear difference in cardiovascular adverse events compared with tamsulosin (alpha‐blocker) (low certainty).
Naftopidil showed no clear difference in sexual adverse events compared with tamsulosin (alpha‐blocker) (low certainty).
Naftopidil showed no clear difference in treatment withdrawals for any reason compared with silodosin (alpha‐blocker) (low certainty).